Loading organizations...
Key people at Nature Biotechnology.
Nature Biotechnology publishes a monthly journal, delivering peer-reviewed research and commentary on the biotechnology sector. It covers novel technological and methodological concepts in biological, biomedical, agricultural, and environmental sciences. The publication addresses molecular engineering, genomics, computational biology, regenerative medicine, and applied immunology, alongside commercial and societal implications.
Established by the Nature publishing group, now Springer Nature, in the mid-1990s, Nature Biotechnology emerged to link scientific discovery with practical applications. Its founding principle was to showcase rigorous advancements while exploring business implications, regulatory aspects, and societal impacts. This bridge between science and its real-world context defined its editorial mission.
The journal serves academic researchers, industry professionals, and policymakers in biotechnology. It informs researchers on business developments and updates the business community on scientific breakthroughs. Nature Biotechnology’s vision is to be a pivotal resource, ensuring wide dissemination of high-quality research and fostering informed dialogue.
Nature Biotechnology is not a company but a prestigious monthly peer-reviewed scientific journal published by Nature Portfolio that focuses on the science and business of biotechnology. It covers cutting-edge research, technology, and commercial developments in biotechnology, including molecular engineering, gene therapy, regenerative medicine, agricultural biotech, and more[1][2].
Nature Biotechnology serves the global scientific and business communities by publishing original research, reviews, and commentary on biotechnology innovations and their commercial applications. It addresses a broad audience including researchers, industry professionals, and policymakers, providing insights into technological advances and market trends. The journal plays a critical role in disseminating knowledge that drives innovation and investment in the biotech sector[1][2].
The journal originated as *Bio/Technology* in 1983 and was relaunched as *Nature Biotechnology* in 1996 to reflect the growing importance and scale of the biotechnology industry. It is edited by Barbara Cheifet and managed by an in-house editorial team. Over time, it has evolved to cover not only scientific breakthroughs but also the commercial, legal, and societal aspects of biotechnology, becoming a leading voice in the field[2][7].
Nature Biotechnology rides the wave of rapid advances in biotechnology, including gene editing, nucleic acid therapeutics, regenerative medicine, and synthetic biology. The timing is critical as biotech innovations increasingly translate into commercial products and therapies impacting healthcare, agriculture, and environmental sustainability. The journal influences the ecosystem by shaping scientific discourse, informing investors and policymakers, and highlighting emerging technologies that drive startup and corporate innovation[1][5].
Looking ahead, Nature Biotechnology will likely continue to expand its coverage of transformative biotech areas such as AI-driven drug discovery, longevity therapeutics, and advanced gene therapies. As biotechnology becomes more integrated with digital technologies and personalized medicine, the journal’s role in bridging science and business will grow. Its influence will evolve by fostering dialogue among researchers, entrepreneurs, and investors, helping to accelerate the translation of biotech innovations into real-world impact[3][5].
In summary, Nature Biotechnology is a leading scientific journal that shapes the biotechnology landscape by publishing high-impact research and business insights, supporting the growth and maturation of the biotech industry worldwide.
Key people at Nature Biotechnology.
